Balchem (BCPC) Q4 2025 earnings summary

Executive summary

• Achieved record full-year sales of $1.037 billion, up 8.8% year-over-year, surpassing $1 billion for the first time, with all three business segments contributing to top and bottom line expansion.

• Delivered record Q4 consolidated sales of $263.6 million, up 9.8% from the prior year quarter, and record adjusted EBITDA and free cash flow.

• Q4 marked the 26th consecutive quarter of year-over-year Adjusted EBITDA growth.

• Announced a 10% increase in annual dividend, marking the seventeenth consecutive year of double-digit growth.

• Over half of annual sales growth came from markets outside the U.S., with robust international expansion.

Financial highlights

• Full-year adjusted EBITDA reached $274.9 million, up 9.8%; Q4 adjusted EBITDA was $67.9 million, up 8.1% year-over-year.

• Q4 adjusted net earnings were $42.3 million, or $1.31 per diluted share, up 14.8%; full year adjusted EPS was $5.15, up 17.8%.

• Q4 GAAP net income was $39.2 million, up 16.8%; full year GAAP net income was $154.8 million, up 20.5%.

• Record free cash flow of $173.6 million for the year; Q4 free cash flow was $51.2 million.

• Net debt reduced to $89.4 million; leverage ratio at 0.3x net debt.

Outlook and guidance

• Management expects continued above-market top and bottom-line growth in 2026, supported by strong competitive positions, innovation, and execution of strategic initiatives.

• Ongoing investments in marketing, clinical research, and international expansion are expected to drive future growth.

• Diversified supply chain and manufacturing footprint mitigate external risks.